Oslo, April 8, 2021 - Navamedic ASA (OSE: NAVA) enters exclusive long term
distribution agreement with Novozymes for PrecisionBiotics Zenflore® in the
Nordics. Through this agreement Navamedic strengthens its position within
consumer healthcare and clinically proven probiotics for specific disease areas.

"We are proud to announce the agreement with Novozymes which expands our product
portfolio within probiotics for specific disease areas in the Nordics. The
agreement is an extension of the great collaboration between our two companies
for PrecisionBiotics Alflorex®, which we launched in 2019, and demonstrates the
value of Navamedic's local competence and insight in important disease areas and
consumer needs" says Kathrine Gamborg Andreassen, CEO in Navamedic ASA.

The special 1714-Serenitas® live culture in Zenflore® was discovered and
developed in partnership with scientists and clinicians from one of the world's
leading centres of research on the microbiome and the gut-brain axis, the APC
Microbiome Institute at University College Cork, Ireland. Clinical studies have
demonstrated that Bifidobacterium longum 1714 improves the ability to handle
stressful situations, supports mental performance and combat mental fatigue.
Zenflore® also contains selected Vitamin Bs which contributes to the reduction
of fatigue and to sustain normal psychological ability.

Kathrine Gamborg Andreassen continues: "Navamedic focuses on products within
specialty pharma, medical nutrition and consumer health. Zenflore® strengthens
our position within consumer healthcare wherein we see a great potential for
development of products and categories - like stress and mental health in this
case. The agreement has a term of eight years with automatic renewal and
strengthens our position in the entire Nordic region, which is our most
important home market."

Steve Howson, Head of B2C at Novozymes One Health commented: "We are delighted
to have reached agreement with our colleagues at Navamedic to launch Zenflore®
in the Nordic region. We already have a strong and successful partnership built
on the launch of Alflorex® in Norway, Denmark and Netherlands over the last few
years. We look forward to working with the Navamedic team to bring Zenflore® to
consumers across the region."

PrecisionBiotics Group has for more than 20 years developed products based upon
living bacterial cultures (probiotics) in collaboration with scientists and
clinicians at the APC Microbiome Institute. Commercialised products are
clinically proven in Europe and USA. PrecisionBiotics Group was acquired by the
Danish company NovoZymes A/S in 2020.



For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com



Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com



About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com



About Novozymes

Novozymes is the world leader in biological solutions. Together with customers,
partners and the global community, we find biological answers to preserve the
planet's resources and help build better lives. As the world's largest provider
of enzyme and microbial technologies, our bioinnovation enables increased health
and nutritional benefits, higher agricultural yields, improved washing, energy
-efficient production, renewable fuel and many other benefits that we rely on
today and in the future. We call it Rethink Tomorrow. www.novozymes.com